絞り込み

16403

広告

「"denda t"[Author]」の検索結果

70件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer.

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.

209PCLINICAL VALIDATION OF A NOVEL MULTIPLEX KIT FOR ALL RAS MUTATIONS IN COLORECTAL CANCER: RESULTS OF RASKET(RAS KEY TESTING) PROSPECTIVE MULTICENTER STUDY.

524PVOICE TRIAL-RESULTS FROM A MULTICENTER PHASE II STUDY OF ASSESSMENT OF CLINICAL EFFICACY AND SAFETY IN CAPECITABINE PLUS INTERMITTENT OXALIPLATIN TOGETHER WITH BEVACIZUMAB AS THE FIRST-LINE THERAPY FOR THE PATIENTS WITH ADVANCED COLORECTAL CANCER.

525PA PHASE III STUDY OF EAGLE COMPARING TWO DOSES OF BEVACIZUMAB COMBINED WITH FOLFIRI IN THE SECOND-LINE SETTING AFTER FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS OXALIPLATIN-BASED THERAPY : KRAS SUBGROUP FINDINGS.

Filter paper-assisted cell transfer (FaCT) technique: A novel cell-sampling technique for intraoperative diagnosis of central nervous system tumors.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.

Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.

A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G.

Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study).

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

[The Different Indications and Treatment Effect between Preoperative Chemotherapy and Preoperative Radiotherapy for Advanced Rectal Cancer].

Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).

Thin films exhibiting multicolor changes induced by formaldehyde-responsive release of anionic dyes.

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.

Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate.

  1. 1
  2. 2
  3. 3
  4. 4
Sort by
※並べ替えは表示に時間がかかります